Cadila Healthcare divests its entire stake in Bremer Pharma, Germany

Bremer Pharma ceases to be subsidiary of Cadila Healthcare

Cadila Healthcare has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company.

The company received consideration at enterprise value of Euro 22,63,431 of which share sale value is Euro 8,27,344 and loan value (extended by Zydus International - a wholly owned subsidiary of the company) is Euro 14,36,087.

Powered by Capital Market - Live News